⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472090 | 1.00 | — | — | |
| SCHEMBL18159714 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL30838026 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL22551866 | 0.97 | TDP1 (0.33) | — | |
| SCHEMBL6844562 | 0.81 | — | — | |
| SCHEMBL25582860 | 0.79 | — | — | |
| SCHEMBL25575437 | 0.79 | — | — | |
| SCHEMBL25575435 | 0.79 | — | — | |
| SCHEMBL8324578 | 0.79 | — | — | |
| SCHEMBL25575438 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118284610-A | Pyrazolotriazine derivatives as CDK9 inhibitors | 原真股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4587437-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4504733-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034165-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4442690-A1 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-118284610-A | Pyrazolotriazine derivatives as CDK9 inhibitors | 原真股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7928122-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |